中国临床药理学杂志Issue(10)：787-789,3.DOI:10.13699/j.cnki.1001-6821.2015.10.006
雷公藤多苷联合盐酸贝那普利治疗免疫球蛋白 A肾病的临床疗效及安全性研究
Clinical efficacy and safety of tripterygium wilfordii glycosides combined with benazepril in the treatment of immunoglobin A nephropathy
摘要
Abstract
Objective To discuss the clinical efficacy and safety for tripterygium wilfordii glycosides combined with benazepril in the treatment of immunoglobin A ( IgA) nephropathy.Methods A total of 65 IgA nephropathy patients confirmed by renal biopsy were included in this study and randomized divided in control group (n=31) and treatment group (n=34).All the included patients were administered with benaze-pril 5-20 mg・ d-1 , and patients in the treatment group were additionally given tripterygium wilfordii glycosides 20 mg, tid.The clinical efficacy , renal function changes and the incidence of adverse reactions between the two groups were recorded after 12 weeks treatment .Results The total effects was 67.74% and 91.18% in the control and treatment group respectively , which showed treatment group was significantly higher than control group ( P <0.05 ) .The renal function ( urine protein , urinary albumin , serum creatinine and glomerular filtration rate ) were signifi-cantly improve after treatment in the treatment groups ( P<0.05 ) .But there was statistical difference only in urine protein foud the control group after treatment ( P <0.05 ) .The adverse incidence were 12.90% and 14.71%respectively in the control and treatment group , which indicated no statistical difference between the two groups ( P >0.05 ) . Conclusion Tripterygium wilfordii glycosides combined with benazepril is promising in the treatment of IgA nephropa -thy with good clinical efficacy and low risk of adverse events .关键词
免疫球蛋白A肾病/雷公藤多苷/盐酸贝那普利/临床疗效/安全性Key words
immunoglobin A nephropathy/tripterygium wilfordii glycosides/benazepril/clinical efficacy/safety分类
医药卫生引用本文复制引用
关毅标,罗福漳,赵学峰..雷公藤多苷联合盐酸贝那普利治疗免疫球蛋白 A肾病的临床疗效及安全性研究[J].中国临床药理学杂志,2015,(10):787-789,3.基金项目
佛山市卫生局医学科研基金资助项目 （）
